Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages

Clinical and Experimental Immunology

Volumn 107, Issue 3, 1997, Pages 569-573

  Hasunuma, Y ^a   Matsuura, E ^a   Makita, Z ^a   Katahira, T ^b   Nishi, S ^a   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b YAMASA CORPORATION   (Japan)

Author keywords

Anti 2 glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid syndrome; Oxidized LDL; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LOW DENSITY LIPOPROTEIN; POLYCYTIDYLIC ACID; POLYINOSINIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNITY; ETIOLOGY; HUMAN; IMMUNIZATION; MACROPHAGE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031051229     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.00300.x     Document Type: Article

References (49)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13:486-9.
2. Harris EN, Gharavi AE, Hughes GRV. Antiphospholipid antibodies. Clin Rheum Dis 1985; 11:591-609.
3. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
4. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336:177-8.
5. Koike T, Matsuura E. What is the 'true' antigen for anticardiolipin antibodies? Lancet 1991; 337:671-2.
6. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148:3885-91.
7. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179:457-62.
8. 2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus 1993; 4 (Suppl. 1): S13-17.
9. 2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood 1996; 87:3262-70.
10. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:1466-74.
11. 2-globulin des Humanserums. Naturwissenschaften 1961; 23:719-24.
12. 2-glycoprotein 1. Proc Natl Acad Sci USA 1984; 81:3640-4.
13. 2-glycoprotein I. Biochem J 1991; 277:387-91.
14. 2-GPI in alternation of anticardiolipin binding. Int Immunol 1991; 3:1217-21.
15. 2-GPI). Gene 1991; 108:293-8.
16. 2-glycoprotein I: the presence of five sushi domains. Biochemistry 1991; 30:11687-94.
17. 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16:511-5.
18. 2-glycoprotein I. Eur J Biochem 1988; 176:629-36.
19. 2-glycoprotein I to human serum lipoproteins. Distribution among density fractions. FEBS Lett 1979; 102:183-6.
20. 2-glycoprotein I. Biochem Biophys Acta 1986; 884:142-9.
21. 2-glycoprotein I : a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66:1086-91.
22. 2-glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63:109-14.
23. 2-glycoprotein I to intralipid: determination of the dissociation constant. Biochem Biophys Res Commun 1979; 90:1305-12.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
25. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Eng J Med 1989; 320:915-24.
26. Krieger M. Structures and functions of multiligand lipoprotein receptors. Ann Rev Biochem 1994; 63:601-37.
27. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76:333-7.
28. Henriksen TE, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981; 78:6499-503.
29. Henriksen TE, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis 1983; 3:149-59.
30. Nishikawa K, Arai H, Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J Biol Chem 1990; 265:5226-31.
31. 1 mice: a model of antiphospholipid syndrome. J Immunol 1992; 149:1063-8.
32. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 43:1345-53.
33. Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. Adv Lipid Res 1968; 6:1-67.
34. McFarlane AS. Efficient trace-labelling of proteins with iodine. Nature 1958; 182:53.
35. Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262:3603-8.
36. Nobel RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968; 9:693-700.
37. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52:302-6.
38. Pearson AM, Rich A, Krieger M. Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices. J Biol Chem 1993; 268:3546-54.
39. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152:653-9.
40. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1956; 37:911-7.
41. Steinbrecher UP, Lougheed M, Kwan WC, Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 1989; 264:15216-23.
42. Nicholson AC, Frieda S, Pearce A, Silverstein RL. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Arteriosclerosis Thromb Vascular Biol 1995; 15:269-75.
43. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 1995; 92:9580-4.
44. Fukasawa M, Adachi H, Hirota K, Tsujimoto M, Amki H, Inoue K. SRBI, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells. Exp Cell Res 1996; 222:246-50.
45. 1 hybrid, a model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981; 154:216-21.
46. 1 mice by haploidentical bone marrow transplantation: possible role for anticardiolipin autoantibodies. Blood 1993; 82:3091-7.
47. Tsakraklidesm VG, Blieden IC, Edwards JE. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J 1974; 87:637-41.
48. Hejtmancik MR, Wright JC, Quint R, Jennings FL. The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1964; 68:119-30.
49. Jonsson H, Nived O, Sturfelt G. Outcome of systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68:141-50.